191 related articles for article (PubMed ID: 16312848)
21. Implantable LHRH agonist for treatment of prostate cancer.
Lajiness MJ
Urol Nurs; 2006 Oct; 26(5):408, 414. PubMed ID: 17078331
[No Abstract] [Full Text] [Related]
22. Addressing bone loss in the cancer survivor.
O'Rourke ME; Ruble K
Oncology (Williston Park); 2009 Feb; 23(2 Suppl Nurse Ed):23-7. PubMed ID: 19856585
[No Abstract] [Full Text] [Related]
23. [Histological investigation of prostate cancer treated with hormonal agents].
Azumi M; Saga Y; Hashimoto H; Kakizaki H
Hinyokika Kiyo; 2006 Oct; 52(10):781-4. PubMed ID: 17131867
[TBL] [Abstract][Full Text] [Related]
24. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
Daskivich TJ; Oh WK
Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
[TBL] [Abstract][Full Text] [Related]
25. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
[TBL] [Abstract][Full Text] [Related]
26. [A phase II pharmacological study of leuprolide acetate 6-month depot, TAP-144-SR (6M), in treatment-Nazve patients with prostatic cancer who received a single subcutaneous or intramuscular injection].
Komura E; Fujimoto T; Takabayashi N; Okamoto H; Akaza H
Gan To Kagaku Ryoho; 2014 May; 41(5):587-93. PubMed ID: 24917003
[TBL] [Abstract][Full Text] [Related]
27. Managing advanced prostate cancer with Viadur (leuprolide acetate implant).
Moul JW; Civitelli K
Urol Nurs; 2001 Dec; 21(6):385-8, 393-4; quiz 395-6. PubMed ID: 11998504
[TBL] [Abstract][Full Text] [Related]
28. Leuprolide implant approved for once-yearly palliative treatment of advanced prostate cancer.
Oncology (Williston Park); 2000 Jun; 14(6):828, 830. PubMed ID: 10887633
[No Abstract] [Full Text] [Related]
29. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leupoprolide acetate in locally advanced prostate cancer. Eur Urol 2006;49:54-8.
Koupparis AJ
Eur Urol; 2006 Sep; 50(3):626-7. PubMed ID: 16750291
[No Abstract] [Full Text] [Related]
30. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
[TBL] [Abstract][Full Text] [Related]
31. [Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
Taguchi T; Koyama H; Yayoi K; Wada T; Takatsuka Y; Sonoo H; Morimoto K; Tominaga T; Abe R; Enomoto K
Gan To Kagaku Ryoho; 1995 Mar; 22(4):495-508. PubMed ID: 7887641
[TBL] [Abstract][Full Text] [Related]
32. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur urol 2006;49:54-8.
Sharma R; Sundar S
Eur Urol; 2007 Apr; 51(4):1146. PubMed ID: 17161523
[No Abstract] [Full Text] [Related]
33. Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection.
Montgomery BS; Borwell JP; Higgins DM
Prostate Cancer Prostatic Dis; 2005; 8(1):66-8. PubMed ID: 15700050
[TBL] [Abstract][Full Text] [Related]
34. Anaphylaxis to leuprolide acetate depot injection during treatment for prostate cancer.
Grant JP; Levinson AW
Clin Genitourin Cancer; 2007 Mar; 5(4):284-6. PubMed ID: 17553209
[TBL] [Abstract][Full Text] [Related]
35. Leuprolide in the treatment of endometrial cancer.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 1997 Sep; 66(3):542. PubMed ID: 9299275
[No Abstract] [Full Text] [Related]
36. [A dose-comparative study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
Taguchi T; Koyama H; Yayoi K; Wada T; Takatsuka Y; Sonoo H; Morimoto K; Tominaga T; Abe R; Enomoto K
Gan To Kagaku Ryoho; 1995 Mar; 22(4):477-94. PubMed ID: 7887640
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
38. Use of the LHRH analogue zoladex depot alone and in combination with cyproterone acetate in the treatment of advanced prostatic cancer.
Di Silverio F; Serio M; Costantini A
J Chemother; 1989 Jul; 1(4 Suppl):1231-4. PubMed ID: 16312846
[No Abstract] [Full Text] [Related]
39. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
40. Injection-site granulomas due to the administration of leuprorelin acetate for the treatment of prostatic cancer.
Shiota M; Tokuda N; Kanou T; Yamasaki H
Fukuoka Igaku Zasshi; 2007 Jul; 98(7):301-4. PubMed ID: 17710895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
